panel q&a session on acquired resistance with drs. reckamp & owonikoko
Published 8 years ago • 74 plays • Length 36:39Download video MP4
Download video MP3
Similar videos
-
28:15
panel q&a session on alk and ros1 acquired resistance with drs. horn and owonikoko
-
19:31
panel q&a session on acquired resistance with drs. riely & horn
-
13:50
questions & answers with drs. doebele and shaw; moderated by craig uthe
-
29:51
current & emerging approaches to acquired resistance for alk/ros1
-
2:16
2020 ttf alk session qa panel using ctc profiling to detect crizotinib resistance on progression
-
26:54
what is acquired resistance to targeted therapy, and why does it occur?
-
3:06
2020 ttf alk session qa panel progression on 2nd-gen alk inhibitor if biopsy shows no alk mutation
-
3:22
acquired resistance in lung cancer treatment - lcvl 2024
-
1:43
2020 ttf alk session qa panel reducing dosage on lorlatinib vs switching to a different agent
-
1:39
2020 ttf egfr session qa panel what is the difference between c797s and c797x
-
2:16
2020 ttf alk session qa panel ros1 patients on immunotherapy chemotherapy combinations
-
4:08
2020 ttf alk/ros session qa panel treatment decisions for simultaneous egfr and ros1 mutation
-
15:16
panel q&a session on patient access and survivorship
-
1:59:57
grace - global resource for advancing cancer education live stream
-
1:50
2020 ttf alk/ros session qa panel the difference in efficacy of tkis in different patients
-
2:26
gracecastuc-061_lung_dr. sandler: my approach to acquired resistance for targeted therapies in lc
-
22:46
mechanisms of alk resistance & implications for treatment
-
47:53
ret/met/braf: initial treatment, acquired resistance, q&a joshua sabari, md joshua bauml, md
-
2:36
2020 ttf alk session qa panel information on the crown trial and firstline lorlatinib